News

Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E. Click here to read more about SNY stock and why it ...
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...
Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...
Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...
Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...
Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, ...
Sanofi wins ‘Top GCC of 2025’ and ‘GCC Country Leader of the Year’ at Zyoin Group workplace summit and awards 2025: Our Bureau, Bengaluru Monday, July 14, 2025, 15:30 Hrs ...
Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...
Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 10 and set a price target of €95.00. The company’s shares closed yesterday at $98.70. Elevat ...
Transplants can be life-saving – but for many, the journey doesn’t end there. Up to 40% of people receiving a stem cell or bone marrow transplant will go on to develop a serious complication known as ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results ...